Wire
CMS wants Medicare Advantage data in Part B drug counts
The agency says Part B-only claims leave out a meaningful slice of spending on drugs billed under Medicare Advantage. That gap matters because the totals feed Medicare’s price-negotiation math.
Medicare beneficiaries whose drugs run through Part B could wind up in a better-counted system if CMS changes how it totals spending. The federal agency wants to add Medicare Advantage (MA) encounter data to traditional Part B claims, so the tally reflects more of what Medicare actually pays for those drugs.
CMS says leaving out Medicare Advantage records excludes a significant share of spending on drugs payable under Part B. If the ledger stays partial, the totals that feed Medicare’s drug-price program can come in too low.
A fuller ledger
In Washington, CMS frames the change as a fairness fix. The agency says the broader calculation would give Part B and Part D drugs equal treatment in the spending tally, instead of measuring Part B with one set of records and leaving out another large piece of the picture.
The proposal is not about whether a drug qualifies for negotiation. It is about the accounting that helps define how big Part B spending really is, and whether a medicine that is used widely in Medicare Advantage plans looks smaller than it should in the totals.
Who feels the difference
That matters to beneficiaries, Medicare Advantage enrollees and drug makers tied to Part B medicines. A more complete count could change how the program sees the spending footprint of those drugs, which is the point of the adjustment: the number should match the bill, not a slice of it.